

1 **Peak oxygen uptake and incident coronary heart disease in a healthy population**  
2 **– The HUNT Fitness Study.**

3

4 Jon Magne Letnes, MD<sup>1,2</sup>, Håvard Dalen, MD, PhD<sup>2,3</sup>, Elisabeth K. Vesterbekkmo, MD<sup>1,2</sup>, Ulrik  
5 Wisløff, PhD<sup>1,4</sup>, Bjarne M. Nes, PhD<sup>1,2</sup>

6

7 <sup>1</sup> Department of circulation and medical imaging, Norwegian University of Science and Technology,  
8 NTNU, Trondheim, Norway

9 <sup>2</sup> Clinic of Cardiology, St. Olavs University Hospital, Trondheim, Norway

10 <sup>3</sup> Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

11 <sup>4</sup> School of Human Movement and Nutrition Science, University of Queensland, Australia

12

13

14

15

16 **Corresponding author:** Bjarne Martens Nes. Mail: [bjarne.nes@ntnu.no](mailto:bjarne.nes@ntnu.no). Phone: (+47) 908 94 295.

17 Address: NTNU, Faculty of Medicine and Health Sciences, Department of Circulation and Medical  
18 Imaging, Postboks 8905, 7491 Trondheim, Norway

19

20

21 **Word count:** 5,013

22

1 **ABSTRACT**

2

3 **Aims:** The majority of previous research on the association between cardiorespiratory fitness (CRF)  
4 and cardiovascular disease is based on indirect assessment of CRF in clinically referred predominantly  
5 male populations. Therefore, our aim was to examine the associations between  $VO_{2peak}$  measured by  
6 the gold-standard method of cardiopulmonary exercise testing and fatal and non-fatal coronary heart  
7 disease in a healthy and fit population.

8

9 **Methods and results:** Data on  $VO_{2peak}$  from 4,527 adults (51% women) with no previous history of  
10 cardiovascular or lung disease, cancer, and hypertension or use of antihypertensive medications  
11 participating in a large population-based health-study (The HUNT3 Study), were linked to hospital  
12 registries and the cause of death registry. Average  $VO_{2peak}$  was 36.0 ml/kg/min and 44.4 ml/kg/min  
13 among women and men, and 83.5% had low ten-year risk of cardiovascular disease at baseline.  
14 Average follow-up was 8.8 years, and 147 participants reached the primary end-point. Multi-adjusted  
15 Cox-regression showed 15% lower risk for the primary end-point per one-MET (metabolic equivalent  
16 task) higher  $VO_{2peak}$  (hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77-0.93), with similar  
17 results across sex. The highest quartile of  $VO_{2peak}$  had 48% lower risk of event compared to the lowest  
18 quartile (HR 0.52, 95% CI 0.33-0.82). Oxygen pulse and ventilatory equivalents of oxygen and carbon  
19 dioxide also showed significant predictive value for the primary end-point.

20

21 **Conclusions:**  $VO_{2peak}$  was strongly and inversely associated with coronary heart disease across the  
22 whole fitness continuum in a low-risk population sample. Implementation of CRF measurements in  
23 clinical practice may improve risk classification and optimize prevention.

24

25 **Keywords.** Cardiorespiratory fitness. Oxygen uptake. Coronary heart disease. Cardiopulmonary  
26 exercise testing. Primary prevention.

# 1 INTRODUCTION

2

3 Despite the decline in mortality from coronary heart disease (CHD),<sup>1</sup> CHD is still responsible for one  
4 third of all deaths in the adult population.<sup>2</sup> As much as fifty percent of the decline in mortality from  
5 myocardial infarction has been attributed to lower case-fatality, probably due to enhanced treatment  
6 options such as percutaneous coronary interventions (PCI) and optimized medical treatment.<sup>3</sup> The  
7 prevalence of CHD in the population therefore remains relatively unchanged.<sup>1</sup> Hence, there is great  
8 potential for further lowering the burden of CHD by early risk detection and preventive strategies.<sup>4</sup>

9 Cardiorespiratory fitness (CRF) is strongly associated with all-cause and cardiovascular  
10 mortality,<sup>5-9</sup> and might even be an important predictor of mortality beyond traditional risk factors such  
11 as hypertension, diabetes, cholesterol levels, and smoking.<sup>10</sup> A more limited number of studies also  
12 suggest that moderate to high CRF in apparently healthy people is associated with delayed CHD  
13 progression and reduced non-fatal events.<sup>6, 8</sup> Hence, a recent statement from the American Heart  
14 Association argued for routine implementation of CRF measurements in clinical practice in order to  
15 improve risk classification and optimize prevention.<sup>10</sup>

16 Most of the evidence, however, is based on studies from a limited number of cohorts including  
17 individuals referred to exercise testing for clinical reasons<sup>11, 12</sup>, and the majority of the mortality risk  
18 burden has been associated with CRF levels below a threshold of 5-6 metabolic equivalents (METs).<sup>13</sup>  
19 Furthermore, women are lacking or underrepresented in most studies,<sup>6, 7, 12, 14</sup> and the generalizability of  
20 findings to apparently healthy, free-living populations is uncertain. Moreover, CRF levels in population  
21 studies are commonly predicted from submaximal or peak workload on a treadmill or cycle ergometer  
22 as opposed to the gold-standard method of cardiopulmonary exercise testing (CPET) by direct gas-  
23 analysis of peak oxygen uptake ( $VO_{2peak}$ ).<sup>5</sup> To our knowledge only two relatively small cohorts,<sup>14, 15</sup>  
24 including middle-aged men, has examined the association between direct measurements of  $VO_{2peak}$  and  
25 risk of cardiovascular events, showing an inverse relationship. Studies investigating the association of  
26  $VO_{2peak}$  and cardiovascular events in healthy population samples are therefore needed.

27 Thus, the aim of this study was to examine the prospective associations between  $VO_{2peak}$ ,  
28 measured by CPET, and fatal or non-fatal coronary heart disease events or revascularization, in a healthy

1 low-risk cohort of both men and women. Secondary, we aimed to assess the associations separately for  
2 myocardial infarction, chronic ischemic heart disease, coronary revascularization, and mortality, as well  
3 as the prognostic value of other CPET measures such as ventilatory equivalents and oxygen pulse.

4

5

6

7

## 1 MATERIAL AND METHODS

2

### 3 Study design and participants

4 The prospective cohort study involved participants from the HUNT3 Fitness Study, a sub-study of the  
5 third wave of the Nord-Trøndelag Health Study (HUNT3). In 2006-2008, all inhabitants in Nord-  
6 Trøndelag county in mid-Norway were invited to participate in HUNT3. Of 93,860 eligible adults,  
7 50,807 inhabitants participated (54.1 %)<sup>16</sup> by answering self-reported questionnaires and undergoing  
8 clinical and biochemical measurements. Participants from four pre-selected municipalities with no  
9 previous history of cardiovascular and lung disease, cancer, sarcoidosis, and hypertension or use of  
10 antihypertensive medications were invited to CPET (n = 12,609). Of these, 5,633 showed up for  
11 exercise testing, and a total of 4,527 completed the exercise test as well as having no other missing  
12 variables for the main analyses. The study was approved by the Regional Committee for Medical  
13 Research Ethics, and the Norwegian Data Inspectorate approved the HUNT Study. All subjects gave  
14 informed consent to participation.

15

### 16 Self-reported and clinical measurements

17 Smoking status (current, former, occasional, and never smoker) and pack-years of cigarettes, alcohol  
18 consumption (frequency of alcohol intake per week over the last 12 months), family history of  
19 cardiovascular disease (CVD) (myocardial infarction or stroke in first degree relative), and leisure-  
20 time physical activity was gathered from self-reported questionnaires. Physical activity was  
21 dichotomized to adherence or non-adherence to physical activity guidelines (detailed information  
22 available in Supplementary data). Clinical examinations were performed by trained personnel  
23 measuring weight to nearest half kilogram, as well as height and waist circumference to nearest  
24 centimetre in standing position. An oscillometry-based Dinamap 845XT (Critikon) was used for  
25 measuring resting heart rate and blood pressure. Blood samples were analysed for non-fasting serum-  
26 levels of total cholesterol, high-density lipoprotein cholesterol (HDL), triglycerides, glucose,  
27 creatinine, and C-reactive protein (CRP). Dyslipidemia was defined as total-cholesterol over 7.0, HDL

1 under 1.3 and 1.0 for men and women respectively, or triglycerides over 1.7. Further information on  
2 measurement of clinical variables in HUNT3 has been described elsewhere.<sup>16</sup>

3

#### 4 **Cardiopulmonary exercise testing**

5 Participants were given a ten-minute warm-up and acclimatization to treadmill walking and running  
6 while establishing initial treadmill inclination and speed at the same time. The participants were  
7 equipped with a heart rate monitor and a face-covering mask before initiating the test on the treadmill.  
8 An individualized ramp-protocol was used where speed (0.5-1 km·h<sup>-1</sup>), inclination (1-2 %), or a  
9 combination of both, was increased roughly every minute or when participants had stable oxygen  
10 uptake values over 30 seconds. Continuous measurement of exhaled gases was done by using a mixing  
11 chamber gas analyser (MetaMax II; Cortex Biophysik GmbH, Leipzig, Germany). Routine gas and  
12 volume calibration was performed at standardized intervals several times per day. Further information  
13 regarding equipment and calibration is available in Supplementary data. Comprehensive data of the  
14 reliability of the measurements has been previously published.<sup>17</sup> Test-retest correlation of oxygen  
15 uptake was 0.99 (p<0.001) and the coefficient of variation was 1.8%. The test was defined as reaching  
16 true VO<sub>2max</sub> if measurements showed a plateau in oxygen consumption as well as a respiratory  
17 exchange ratio (RER) above 1.05. In the present study both tests meeting criteria for VO<sub>2max</sub> as well as  
18 tests classified as VO<sub>2peak</sub> are labelled VO<sub>2peak</sub>. Oxygen pulse was calculated as maximal oxygen  
19 consumption in millilitres divided by heart-rate at peak exercise. Ventilatory efficiency equivalents  
20 was calculated as minute ventilation divided by CO<sub>2</sub> ventilation or O<sub>2</sub> consumption in litres per minute  
21 at peak and steady state submaximal exercise.

22

#### 23 **Follow-up and information on end-points**

24 Follow-up was ensured by linking baseline data from The HUNT3 Study to a local, validated hospital  
25 database (Nord-Trøndelag Hospital Trust myocardial infarction registry), the regional health trust  
26 database on diagnoses and procedures, and the Norwegian Cause of Death Registry (NCDR). We used  
27 ICD-10 (International Classification of Disease-10) codes I20, I21, I24, I25 to define end-points of  
28 CHD. Information on coronary revascularization including percutaneous coronary intervention (PCI)

1 and coronary artery bypass graft surgery (CABG) was based on relevant codes from Nomesco  
2 classification of surgical and radiological procedures (NCSP and NCRP). Information on cause and  
3 date of death was gathered from the NCDR. Death from CHD was based ICD-10 codes I20-I25.  
4 Primary end-point was defined as diagnosis of, or death from, CHD, or coronary revascularization  
5 (PCI or CABG), whichever came first.

## 6 7 **Statistical analyses**

8 Ten-year risk of CVD was calculated and classified as low, medium or high based on the recently  
9 published NORRISK2 risk prediction algorithm (detailed information available in Supplementary  
10 data).<sup>18</sup> The Cox proportional hazards model was employed with attained age as the time scale. Time  
11 under risk was calculated as time since participation in the HUNT3 Fitness Study (ranging from June  
12 14<sup>th</sup> 2007 until June 19<sup>th</sup> 2008) until censoring (death of non-coronary cause), event, or end of follow-  
13 up (December 31<sup>st</sup> 2016). The proportional hazards assumption was investigated by testing Schoenfeld  
14 residuals. Analyses were performed with  $VO_{2peak}$  expressed as a continuous variable by METs (one  
15 MET equals ~3.5 ml/kg/min) and by comparing quartiles of  $VO_{2peak}$ . Quartiles of  $VO_{2peak}$  was age and  
16 sex-specific by generating percentiles of  $VO_{2peak}$  in categories of sex and age (in deciles) before  
17 merging these in quartiles of  $VO_{2peak}$  (Q1 to Q4). This ensured equal age and gender distribution  
18 across quartiles. Main analyses were adjusted for age and sex in model 1, and in addition, smoking  
19 status, alcohol intake, and family history of CVD in model 2. Adjustment for BMI was included in  
20 sub-analyses performed on exercise variables not being weight scaled. We examined evidence of  
21 interaction with  $VO_{2peak}$  across covariates, and test for linear trend across categories Q1 to Q4 was  
22 performed by tests for log-linearity of the hazard ratios. Results are presented as hazard ratios for  
23 effect estimates and 95% confidence intervals (95% CIs) for evaluation of precision. Analyses were  
24 performed using STATA15.1 (StataCorp, Texas, US).

25

26

# 1 RESULTS

2

## 3 **Characteristics of the population**

4 Baseline characteristics of the 4,527 participants are shown in Table 1. Briefly, mean age was  
5 48.2 (standard deviation (SD) 13.5, range 19 to 89) years, and gender distribution was  
6 balanced (51% women). Average  $VO_{2peak}$  in the population was 36.0 ml/kg/min and 44.4  
7 ml/kg/min among women and men, respectively. The pre-defined  $VO_{2max}$  criteria were  
8 reached in 80% of participants. Cut-offs of  $VO_{2peak}$  for Q1 to Q4 across sex and ten-year age  
9 groups is found in Supplementary table 1. Levels of cardiovascular risk-factors were  
10 consistently decreasing from Q1 through Q4 (except alcohol use being higher in higher  
11 quartiles of  $VO_{2peak}$ ). Clustering of cardiovascular risk at baseline was generally low, as  
12 83.5% had low ten-year risk of CVD and mortality as measured by the NORRISK2 risk  
13 prediction model.

14

## 15 **Peak oxygen uptake and primary end-point**

16 During a total follow-up time of 40,060 person-years (mean 8.8, SD 1.0) 147 participants (3.3%)  
17 reached the composite primary end-point of diagnosis of or death from CHD, or intervention by PCI  
18 or CABG. Incidence rate of primary end-point was 3.7 events per 1000 person-years. In the combined  
19 analyses of men and women, the risk for primary end-point was 16% (95% CI 8-23) lower per one  
20 MET higher  $VO_{2peak}$  after adjustment for age and sex (model 1), and 15% (95% CI 7-23) when  
21 additionally adjusted for smoking status, alcohol use and family history of CVD in the multi-adjusted  
22 model 2 (Table 2). The same direction and comparable magnitude of effects were seen in analyses  
23 stratified by sex. The Kaplan-Meier graph (Figure 1) illustrates the higher event-free survival from the  
24 primary composite end-point for the higher quartiles of  $VO_{2peak}$ . Analyses by quartiles of  $VO_{2peak}$   
25 showed approximately 50% (95% CI 18-67) lower risk in Q4 compared to Q1 and testing for trend  
26 across quartiles of  $VO_{2peak}$  showed a significant linear trend ( $p < 0.005$  for model 1 and 2 in combined  
27 analyses). Further, when subdivided by baseline  $VO_{2peak}$  level, participants in the highest quartiles had



1 similar protective effect per one MET higher  $VO_{2peak}$ . There was no evidence of statistical interaction  
2 between covariates in model 1 and 2.

3

#### 4 **Sub-analyses**

5 Analyses with myocardial infarction, chronic ischemic heart disease, coronary revascularization by  
6 PCI or CABG, and mortality as respective end-points is presented in Table 3. In general, the effect  
7 estimates were in line with findings in the main analyses. However, noticeably the association with  
8 all-cause mortality was weak, with a 6% (95% CI -5-16) lower mortality risk per one MET higher  
9  $VO_{2peak}$  in the multi-adjusted model. Mortality incidence rate was 2.2 per 1000 person-years (91 deaths  
10 of any cause). Malignant disease was the leading cause of death (48%), while cardiovascular and  
11 respiratory disease accounted for only 20% and 3% of deaths during follow-up, respectively.

12 Hazard ratios for the primary end-point in the analyses stratified by presence of cardiovascular  
13 risk factors (blood pressure > 140/90, diabetes, obesity, smoking status, dyslipidemia, and physical  
14 activity adherence) showed results consistent to findings in the main analyses (data not shown),  
15 suggesting no effect modification by baseline levels of cardiovascular risk factors. Stratified analyses  
16 for primary end-point by groups of ten-year risk of CVD (n=4,149) gave similar results; low-medium  
17 risk group: 14% (95% CI 2-24) lower risk per one MET higher  $VO_{2peak}$ , and high-risk group: 16%  
18 (95% CI 0-29) lower risk per one MET higher  $VO_{2peak}$  (multi-adjusted model). One percent higher ten-  
19 year cardiovascular risk were associated with 12% (95% CI 8-16) higher risk of the primary end-point.

20 Cox regression analyses on oxygen pulse showed 8% (95% CI 2-13) lower risk for primary  
21 end-point per unit higher value adjusted as for in the multi-adjusted model plus adjustment for BMI.  
22 We also tested whether the oxygen equivalent ( $EqVO_2$ ) at peak exercise was associated with primary  
23 end-point (adjusted as for the multi-adjusted model plus BMI). These analyses gave a 3% (95% CI 0-  
24 6) and 5% (95% CI -1-11) higher risk per unit higher ratio for peak (n=4,497) and submaximal  
25 (n=2,506) values, respectively. Only sixteen participants had  $EqVO_2$  values above the upper normal  
26 limit of 50. Analyses per unit higher  $EqVCO_2$  gave 4% increased risk for primary end-point for peak  
27 (95% CI 0-8, n=4,497) and submaximal values (95% CI -3-13, n=2,503), respectively. Having values  
28 of  $EqVCO_2$  above the upper normal limit of 30 was associated with 39% (95% CI -6-106) higher risk

1 of the primary end-point. Additional results from these analyses are available in supplementary  
2 material (Supplementary table 2).

3

#### 4 **Sensitivity analyses**

5 In analysis for the primary end-point after adjusting for BMI, systolic blood pressure, dyslipidemia, C-  
6 reactive protein, and diabetes in addition to the variables in model 1 and 2 the HR was slightly  
7 attenuated to 0.90 (95% CI 0.81-1.00, n=4,421). Separate analyses for the primary end-point excluding  
8 first two years of follow-up showed similar results as the main analyses, HR 0.89 (95% CI 0.81-0.98)  
9 in model 2. We also performed analyses for primary end-point on those subjects reaching the pre-  
10 defined VO<sub>2max</sub> criteria, with similar results as in the main analyses (model 2: HR 0.83, 95% CI 0.74-  
11 0.93). Time on study instead of attained age was tested as time scale for the main analyses without  
12 notable effect on estimates.

13

14

15

## 1 **DISCUSSION**

2

3 Our results show that peak oxygen uptake ( $VO_{2peak}$ ) is inversely related to the risk of coronary heart  
4 disease in healthy men and women. The influence of  $VO_{2peak}$  was similar for both acute diagnoses like  
5 myocardial infarction and chronic diagnoses such as angina pectoris, and the reduced risk with higher  
6  $VO_{2peak}$  was similar both in fit and unfit sub-populations. Further, ventilatory equivalents and oxygen  
7 pulse were also associated with incident coronary heart disease.

8

### 9 **$VO_{2peak}$ and coronary heart disease**

10 Our main finding of 17% (men) and 12% (women) lower adjusted risk of CHD per one MET higher  
11  $VO_{2peak}$  is in line with the large meta-analysis from 2009 by Kodama et al.<sup>9</sup> estimating a 15% lower  
12 risk per one MET higher exercise capacity. In general, our findings support several earlier studies  
13 describing an inverse relationship between cardiorespiratory fitness and fatal<sup>12, 19, 20</sup> and non-fatal<sup>6, 8, 21</sup>  
14 CHD. Even though precision was lower in women, the consistent size and direction of estimates  
15 makes erroneous conclusions less likely.

16 The association between fitness and CHD was strong despite the fit population sample in this  
17 study. In fact, the average  $VO_{2peak}$  among women in this study was higher than the average among  
18 men in other studies.<sup>6, 8, 14, 22</sup> The average sixty-year-old male in our study had roughly the same fitness  
19 level as the group with highest estimated fitness in the meta-analysis by Kodama et al.<sup>9</sup> A 28% higher  
20  $VO_{2peak}$  compared to the normal material from the US FRIEND cohort<sup>23</sup> further confirms the fit  
21 sample of our participants. Test for trend across the quartiles of  $VO_{2peak}$  showed a significant linear  
22 relationship, and when analysing within the highest-fit quartile of  $VO_{2peak}$  we found the same  
23 association per one MET higher  $VO_{2peak}$ , indicating that higher cardiorespiratory fitness is protective  
24 with no apparent upper threshold. Cut-offs of CRF for risk reduction have, however, been  
25 recommended earlier. Exercise capacity <5 METs has been proposed as a single threshold of increased  
26 risk,<sup>13</sup> as well as cut-offs of 8 and 6 METs for fifty year old men and women, respectively, in another  
27 study.<sup>9</sup> Our results suggest that there is still a large potential for risk-reduction even when having CRF  
28 beyond such thresholds, and implicitly, thresholds may vary between populations.

1 The risk reduction of CHD per one MET higher  $VO_{2peak}$  was consistent across stratified  
2 analyses by presence of the cardiovascular risk factors, which is in line with findings from several  
3 other studies.<sup>19, 24</sup>

4 The associations of  $VO_{2peak}$  to all-cause mortality was not statistically significant, and the  
5 effect-estimates of 6% lower relative risk of all-cause mortality per one MET is somewhat lower than  
6 findings from a large meta-analysis.<sup>9</sup> The fact that mortality from CVD and respiratory diseases  
7 contributed to only 23% of deaths in total may explain these weak associations.

8 Our results showed a clear predictive value of oxygen pulse, a less studied CPET variable, for  
9 future CHD. Similar findings was recently shown in a publication from the Kuopio Ischemic Heart  
10 Disease cohort.<sup>25</sup> The oxygen pulse trajectory is included for judgment of myocardial ischemia as a  
11 non-invasive measure of stroke volume,<sup>26</sup> and our findings support the prognostic value of this  
12 parameter, even without assessing the trajectory during test. Ventilatory equivalents for oxygen  
13 ( $EqVO_2$ ) and carbon dioxide ( $EqVCO_2$ ) at peak exercise also showed predictive value of CHD, while  
14 missing data of submaximal measures gave low precision of estimates especially for  $EqVCO_2$ .

## 16 **Strengths and limitations**

17 Our study has several methodological strengths. Firstly, cardiorespiratory fitness was measured by  
18 direct assessment of peak oxygen consumption during maximal exercise, and this study is the first to  
19 use this gold-standard method in a healthy sample of the general population to evaluate associations  
20 with cardiovascular events and mortality. The precise measurements of exposure may have  
21 compensated somewhat for the relatively few end-points accumulated over the follow-up period. A  
22 study from the FRIEND database showed significant differences between cardiorespiratory fitness  
23 reference data based on direct measurement of  $VO_{2peak}$ , and  $VO_{2peak}$  estimated from exercise test  
24 data.<sup>23</sup> The same study found that there were notable differences especially in the extremes of  
25 estimated fitness. This reflects the need for follow-up studies based on directly measured  
26 cardiorespiratory fitness. Definition of end-points by linkage to hospital databases and national  
27 registries ensured high-quality data with negligible loss to follow-up. We did not have specific  
28 information on emigration during follow-up, however emigration from the county is known to be very

1 low.<sup>16</sup> The healthy population also reduced the risk of reverse confounding from clinical or subclinical  
2 disease as an explanation for the association. Sensitivity analyses with exclusion of participants with  
3 events during the first two years of follow-up supported this assumption.

4         Participating in voluntary exercise testing introduces the possibility of self-selection towards  
5 more active participants, which may reduce external validity. However, an earlier study compared the  
6 HUNT3 Fitness population with the healthy part of the total HUNT3 population and found a similar  
7 cardiovascular risk profile in men and women, but the Fitness study participants were slightly more  
8 active, weighed less, and had lower waist circumference.<sup>27</sup> The same study showed that the prevalence  
9 of cardiovascular risk factors was slightly lower in the Fitness population compared to the general  
10 HUNT3 population (5.6% vs 6.4%).

## 11 12 **Clinical implications**

13 The update on clinical recommendations for CPET from 2016 highlighted the potential for risk-  
14 stratification and prevention of non-communicable disease prevention among apparently healthy  
15 individuals.<sup>28</sup> Our results confirm that the level of CRF predicts CHD, with a preventive influence of  
16 higher values, in a healthy free-living population. Higher  $VO_{2peak}$  was protective against both chronic  
17 and acute ischemic heart disease, respectively. Further, motivation for primary disease prevention by  
18 medical therapy in the population is known to be low,<sup>29</sup> partly due to low adherence, high costs and  
19 potential side-effects. Exercise on the other hand is associated with healthy living and reduced  
20 morbidity, and the potential for primary prevention is great, and not fully exploited.<sup>4</sup> Taking full  
21 advantage of exercise as (preventive) medicine is an important challenge to the society as the scientific  
22 evidence show great health-impact of as little as one MET higher CRF. Such a modest increase in  
23 CRF is easily achieved over a few months of regular exercise,<sup>30</sup> and thus, exercise may be an efficient  
24 way of reducing the cardiovascular risk.

## 25 26 **Conclusion**

27 In conclusion, peak oxygen uptake was strongly and inversely related to coronary heart disease in a  
28 large cohort of apparently healthy and low-risk men and women. These findings support the notion

1 that  $VO_{2peak}$  has predictive value along the whole fitness continuum and implementation of CRF  
2 measurements in clinical practice may improve risk classification and optimize prevention.  
3 Interventions aiming to increase  $VO_{2peak}$  may have substantial benefits in reducing the burden of  
4 coronary heart disease.

5

## 6 **FUNDING**

7 The current study was funded by The Liaison Committee for education, research and innovation in  
8 Central Norway.

9

## 10 **ACKNOWLEDGEMENTS**

11 The Nord-Trøndelag Health Study (The HUNT Study) is a collaboration between HUNT Research  
12 Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology  
13 NTNU), Nord-Trøndelag County Council, Central Norway Regional Health Authority, and the  
14 Norwegian Institute of Public Health. We want to thank clinicians and other employees at Nord-  
15 Trøndelag Hospital Trust for support and for contributing to data collection in this research project.

16

17

## 18 **CONFLICT OF INTEREST**

19 None declared.

20

21

22

23

24

## 1 REFERENCES

2

- 3 1. Bhatnagar P, Wickramasinghe K, Wilkins E and Townsend N. Trends in the  
4 epidemiology of cardiovascular disease in the UK. *Heart*. 2016;102:1945-1952.
- 5 2. Sanchis-Gomar F, Perez-Quilis C, Leischik R and Lucia A. Epidemiology of coronary  
6 heart disease and acute coronary syndrome. *Ann Transl Med*. 2016;4:256.
- 7 3. Smolina K, Wright FL, Rayner M and Goldacre MJ. Determinants of the decline in  
8 mortality from acute myocardial infarction in England between 2002 and 2010: linked  
9 national database study. *BMJ*. 2012;344:d8059.
- 10 4. Ford ES and Capewell S. Proportion of the decline in cardiovascular mortality disease  
11 due to prevention versus treatment: public health versus clinical care. *Annu Rev Public*  
12 *Health*. 2011;32:5-22.
- 13 5. Harber MP, Kaminsky LA, Arena R, Blair SN, Franklin BA, Myers J and Ross R. Impact  
14 of Cardiorespiratory Fitness on All-Cause and Disease-Specific Mortality: Advances Since  
15 2009. *Prog Cardiovasc Dis*. 2017;60:11-20.
- 16 6. Khan H, Jaffar N, Rauramaa R, Kurl S, Savonen K and Laukkanen JA. Cardiorespiratory  
17 fitness and nonfatal cardiovascular events: A population-based follow-up study. *Am Heart J*.  
18 2017;184:55-61.
- 19 7. Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr., Clark DG, Cooper KH and Gibbons LW.  
20 Physical fitness and all-cause mortality. A prospective study of healthy men and women.  
21 *JAMA*. 1989;262:2395-401.
- 22 8. Tikkanen E, Gustafsson S and Ingelsson E. Associations of Fitness, Physical Activity,  
23 Strength, and Genetic Risk With Cardiovascular Disease: Longitudinal Analyses in the UK  
24 Biobank Study. *Circulation*. 2018.
- 25 9. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, Sugawara A, Totsuka K,  
26 Shimano H, Ohashi Y, Yamada N and Sone H. Cardiorespiratory fitness as a quantitative  
27 predictor of all-cause mortality and cardiovascular events in healthy men and women: a  
28 meta-analysis. *JAMA*. 2009;301:2024-35.
- 29 10. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, Haskell WL, Kaminsky  
30 LA, Levine BD, Lavie CJ, Myers J, Niebauer J, Sallis R, Sawada SS, Sui X, Wisloff U, American  
31 Heart Association Physical Activity Committee of the Council on L, Cardiometabolic H,  
32 Council on Clinical C, Council on E, Prevention, Council on C, Stroke N, Council on Functional  
33 G, Translational B and Stroke C. Importance of Assessing Cardiorespiratory Fitness in Clinical  
34 Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American  
35 Heart Association. *Circulation*. 2016;134:e653-e699.
- 36 11. Myers J, Prakash M, Froelicher V, Do D, Partington S and Atwood JE. Exercise capacity  
37 and mortality among men referred for exercise testing. *N Engl J Med*. 2002;346:793-801.
- 38 12. Kokkinos PF, Faselis C, Myers J, Narayan P, Sui X, Zhang J, Lavie CJ, Moore H, Karasik P  
39 and Fletcher R. Cardiorespiratory Fitness and Incidence of Major Adverse Cardiovascular  
40 Events in US Veterans: A Cohort Study. *Mayo Clin Proc*. 2017;92:39-48.
- 41 13. Kokkinos P, Myers J, Faselis C, Panagiotakos DB, Doumas M, Pittaras A, Manolis A,  
42 Kokkinos JP, Karasik P, Greenberg M, Papademetriou V and Fletcher R. Exercise capacity and  
43 mortality in older men: a 20-year follow-up study. *Circulation*. 2010;122:790-7.
- 44 14. Laukkanen JA, Lakka TA, Rauramaa R, Kuhanen R, Venalainen JM, Salonen R and  
45 Salonen JT. Cardiovascular fitness as a predictor of mortality in men. *Arch Intern Med*.  
46 2001;161:825-31.

- 1 15. Talbot LA, Morrell CH, Metter EJ and Fleg JL. Comparison of cardiorespiratory fitness  
2 versus leisure time physical activity as predictors of coronary events in men aged < or = 65  
3 years and > 65 years. *Am J Cardiol.* 2002;89:1187-92.
- 4 16. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, Bratberg G,  
5 Heggland J and Holmen J. Cohort Profile: the HUNT Study, Norway. *Int J Epidemiol.*  
6 2013;42:968-77.
- 7 17. Loe H, Rognmo O, Saltin B and Wisloff U. Aerobic capacity reference data in 3816  
8 healthy men and women 20-90 years. *PLoS One.* 2013;8:e64319.
- 9 18. Selmer R, Iglund J, Ariansen I, Tverdal A, Njolstad I, Furu K, Tell GS and Klemsdal TO.  
10 NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction. *Eur*  
11 *J Prev Cardiol.* 2017;24:773-782.
- 12 19. Farrell SW, Finley CE, Barlow CE, Willis BL, DeFina LF, Haskell WL and Vega GL.  
13 Moderate to High Levels of Cardiorespiratory Fitness Attenuate the Effects of Triglyceride to  
14 High-Density Lipoprotein Cholesterol Ratio on Coronary Heart Disease Mortality in Men.  
15 *Mayo Clin Proc.* 2017.
- 16 20. Gander JC, Sui X, Hebert JR, Hazlett LJ, Cai B, Lavie CJ and Blair SN. Association of  
17 Cardiorespiratory Fitness With Coronary Heart Disease in Asymptomatic Men. *Mayo Clin*  
18 *Proc.* 2015;90:1372-9.
- 19 21. Berry JD, Pandey A, Gao A, Leonard D, Farzaneh-Far R, Ayers C, DeFina L and Willis B.  
20 Physical fitness and risk for heart failure and coronary artery disease. *Circ Heart Fail.*  
21 2013;6:627-34.
- 22 22. Al-Mallah MH, Juraschek SP, Whelton S, Dardari ZA, Ehrman JK, Michos ED,  
23 Blumenthal RS, Nasir K, Qureshi WT, Brawner CA, Keteyian SJ and Blaha MJ. Sex Differences  
24 in Cardiorespiratory Fitness and All-Cause Mortality: The Henry Ford Exercise Testing (FIT)  
25 Project. *Mayo Clin Proc.* 2016;91:755-62.
- 26 23. Kaminsky LA, Arena R and Myers J. Reference Standards for Cardiorespiratory Fitness  
27 Measured With Cardiopulmonary Exercise Testing: Data From the Fitness Registry and the  
28 Importance of Exercise National Database. *Mayo Clin Proc.* 2015;90:1515-23.
- 29 24. Katzmarzyk PT, Church TS and Blair SN. Cardiorespiratory fitness attenuates the  
30 effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men.  
31 *Arch Intern Med.* 2004;164:1092-7.
- 32 25. Laukkanen JA, Araujo CGS, Kurl S, Khan H, Jae SY, Guazzi M and Kunutsor SK. Relative  
33 peak exercise oxygen pulse is related to sudden cardiac death, cardiovascular and all-cause  
34 mortality in middle-aged men. *Eur J Prev Cardiol.* 2018;25:772-782.
- 35 26. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R, Fletcher GF,  
36 Forman DE, Kitzman DW, Lavie CJ, Myers J, European Association for Cardiovascular P,  
37 Rehabilitation and American Heart A. EACPR/AHA Scientific Statement. Clinical  
38 recommendations for cardiopulmonary exercise testing data assessment in specific patient  
39 populations. *Circulation.* 2012;126:2261-74.
- 40 27. Aspenes ST, Nilsen TI, Skaug EA, Bertheussen GF, Ellingsen O, Vatten L and Wisloff U.  
41 Peak oxygen uptake and cardiovascular risk factors in 4631 healthy women and men. *Med*  
42 *Sci Sports Exerc.* 2011;43:1465-73.
- 43 28. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J and Lavie CJ. 2016 Focused Update:  
44 Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific  
45 Patient Populations. *Circulation.* 2016;133:e694-711.
- 46 29. Biondi-Zoccai G, Wu Y, Serrano CV, Jr., Frati G, Agostoni P and Abbate A. Aspirin  
47 underuse, non-compliance or cessation: definition, extent, impact and potential solutions in



1 the primary and secondary prevention of cardiovascular disease. *Int J Cardiol.* 2015;182:148-  
2 54.

3 30. Weston KS, Wisloff U and Coombes JS. High-intensity interval training in patients with  
4 lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. *Br J Sports*  
5 *Med.* 2014;48:1227-34.

6

7

# 1 TABLES

2

Table 1. Baseline characteristics of the study population stratified by sex

	Women	Men
n	2,316	2,211
Age (years, mean SD)	47.65 (13.6)	48.76 (13.5)
Physical measurements		
Waist circumference (cm, mean SD)	85.8 (10.6)	94.6 (9.1)
Body mass index (kg/cm <sup>2</sup> , mean SD)	25.4 (3.9)	26.6 (3.2)
Systolic blood pressure (mmHg, mean SD)	123.5 (15.4)	132.0 (14.3)
Diastolic blood pressure (mmHg, mean SD)	69.9 (9.8)	76.4 (10.3)
Resting heart rate (beats/min, mean SD)	67.5 (10.0)	64.6 (10.9)
Biochemical measurements		
Total cholesterol (mmol/l, mean SD)	5.43 (1.11)	5.48 (1.02)
HDL cholesterol (mmol/l, mean SD)	1.53 (0.34)	1.25 (0.29)
Triglycerides (mmol/l, mean SD)	1.23 (0.67)	1.79 (1.12)
Glucose, non-fasting (mmol/l, mean SD)	5.21 (1.01)	5.53 (1.51)
Creatinine (umol/l, mean SD)	72.2 (10.7)	85.8 (11.4)
C-reactive protein (mg/l, median IQR)	0.80 (1.40)	0.90 (1.20)
Behavioural		
Regular alcohol intake* (%)	15.2	21.2
Pack years of cigarettes (n, median IQR)	6.4 (11.7)	8.4 (15.6)
Smoker (%)	19.3	18.0
Physically active (%) <sup>†</sup>	26.2	29.5
Disease in first-degree relative		
Cardiovascular disease (%)	19.4	17.7
Cardiovascular risk <sup>‡</sup>		

Low	94.3	72.3
Moderate	2.9	9.9
High	2.8	17.9

Exercise testing variables

VO <sub>2peak</sub> (ml/min/kg, mean SD)	36.0 (7.8)	44.4 (9.2)
VO <sub>2max</sub> criteria met (%)	76.9	83.3
RER <sub>peak</sub> (mean SD)	1.12 (0.07)	1.12 (0.07)
Heart rate <sub>peak</sub> (beats/min, mean SD)	179.1 (14.8)	180.1 (15.5)
Oxygen pulse <sub>peak</sub> (ml/heart beat)	13.9 (2.6)	21.0 (3.9)
EqVCO <sub>2peak</sub>	24.48 (2.83)	24.47 (2.94)
EqVO <sub>2peak</sub>	33.33 (4.67)	33.25 (4.71)

SD, standard deviation; IQR, interquartile range; HDL, high-density lipoprotein; RER, respiratory exchange ratio; EqVCO<sub>2</sub>, ventilatory equivalent for carbon dioxide; EqVO<sub>2</sub>, ventilatory equivalent for oxygen

\* Regular alcohol intake over once per week.

† Adherence to physical activity guidelines.

‡ Ten-year cardiovascular risk assessed by NORRISK2 risk prediction algorithm.

Table 2. Hazard ratios for primary end-point\* per one MET higher VO<sub>2peak</sub>, and by quartiles of VO<sub>2peak</sub>

		Model 1			Model 2	
		Events (n)	HR	95% CI	HR	95% CI
Total		Per 1-MET	0.84	0.77-0.92	0.85	0.77-0.93
	Q1	58	1	-	1	-
	Q2	34	0.58	0.38-0.88	0.58	0.38-0.90
	Q3	27	0.46	0.29-0.73	0.48	0.30-0.76
	Q4	28	0.49	0.31-0.78	0.52	0.33-0.82
Men		Per 1-MET	0.82	0.75-0.91	0.83	0.75-0.92
	Q1	44	1	-	1	-
	Q2	23	0.50	0.30-0.83	0.51	0.31-0.85
	Q3	20	0.43	0.26-0.74	0.46	0.27-0.79
	Q4	18	0.40	0.23-0.70	0.43	0.24-0.75
Women		Per 1-MET	0.89	0.74-1.08	0.88	0.73-1.08
	Q1	14	1	-	1	-
	Q2	11	0.79	0.36-1.74	0.76	0.35-1.69
	Q3	7	0.51	0.21-1.28	0.49	0.20-1.22
	Q4	10	0.79	0.35-1.78	0.77	0.34-1.77

\*Coronary heart disease, revascularization by PCI or CABG, coronary heart disease mortality.; HR, hazard ratio; CI, confidence interval; Q1-Q4, quartile 1 to 4;

Model 1: adjusted for age and sex

Model 2: model 1 + smoking status, alcohol use, and family history of CVD.

Table 3. Hazard ratio per one MET higher  $VO_{2peak}$  for secondary end-points

	Events (n)	Model 1		Model 2	
		HR	95% CI	HR	95% CI
Myocardial infarction	74	0.80	0.70-0.90	0.80	0.70-0.91
Chronic ischemic heart disease	74	0.89	0.79-1.01	0.90	0.79-1.02
Coronary revascularization	85	0.83	0.74-0.93	0.83	0.74-0.94
All-cause mortality	91	0.90	0.80-1.01	0.94	0.84-1.05
Cardiovascular mortality	18	0.73	0.54-0.98	0.78	0.58-1.04


MET, metabolic equivalent task; HR, hazard ratio; CI, confidence interval.

Model 1: adjusted for age and sex

Model 2: model 1 + smoking status, alcohol use, and family history of CVD.

1 **FIGURES**

2



3

4 Figure 1: Kaplan-Meier curve for survival from primary end-point according to age and sex-specific  
5 quartiles of  $VO_{2peak}$  (Q1-Q4).

6



## 1 **SUPPLEMENTARY DATA**

2

### 3 **Supplementary methods**

#### 4 *Cardiopulmonary exercise testing*

5 The heart rate monitor used for the test was a Polar S610 or Polar RS300 (Polar, Kempele, Finland).

6 The face-covering mask was a Hans-Rudolph V (Shawnee, US). The treadmill was a DK7830 (DK  
7 City, Taichung, Taiwan).

8 Two-point gas calibration towards carbon dioxide and oxygen of known concentrations was  
9 done before the first test every day, as well as after every fifth test throughout the day. Volume  
10 calibration was done before the first test every day as well as after every third test using a 3L  
11 standardized syringe (Calibration syringe D, Sensormedics, CareFusion, San Diego, CA, USA).  
12 Ambient air was checked before each test.

13

#### 14 *Self-reported information on physical activity*

15 Physical activity was dichotomized to adherence or non-adherence to physical activity guidelines  
16 defined as minimum 75 minutes per week of high-intensity exercise or minimum 150 minutes per  
17 week of moderate intensity exercise. This was calculated by combining average frequency (never, less  
18 than once a week, once a week, two to three times a week, or almost every day), duration (less than 15  
19 minutes, 15-29 minutes, 30 to 60 minutes, over 60 minutes) and average intensity (graded as 6-20 on  
20 the scale of rated perceived exertion) of weekly leisure-time physical activity. Minutes of leisure time  
21 physical activity was calculated as average time (minutes) spent exercising per session multiplied with  
22 average frequency of exercise per week. Moderate and high intensity was defined as rate of perceived  
23 exertion 13-14 and 15-20, respectively.

24

#### 25 *Utilization of the NORRISK2 risk-prediction algorithm*

26 Ten-year risk of cardiovascular disease was calculated and classified as low, medium or high based on  
27 the recently published NORRISK2 risk prediction algorithm.<sup>18</sup> High risk: > 5% ten-year risk in age-



1 group < 54 years, >10% ten-year risk in age-group 55-64 years, and > 15% ten-year risk in the age-  
 2 group  $\geq$  65 years. Low risk: < 4% ten-year risk in age-group < 54 years, <8% ten-year risk in age-  
 3 group 55-64 years, and < 12% ten-year risk in the age-group  $\geq$  65 years. We adapted the mentioned  
 4 risk calculator to our population by including ages under 45 years of age in the lowest age-group  
 5 (originally 45-54 years), and ages over 74 years in the oldest age-group (originally 65-74 years).

6

## 7 **Supplementary tables**

Supplementary table 1. Cut-offs for  $VO_{2peak}$  in ml/kg/min by age, sex and quartiles of  $VO_{2peak}$

			Q1		Q2		Q3		Q4	
	Age	n	min	max	min	max	min	max	min	max
<b>Men</b>	<30	219	27.2	48.5	48.8	54.6	54.7	59.3	59.4	75.1
	30-39	379	21.6	43.2	43.2	48.3	48.4	54.0	54.0	69.9
	40-49	569	26.8	41.5	41.5	46.9	46.9	51.3	51.3	71.3
	50-59	563	21.8	36.2	36.2	41.3	41.4	46.5	46.5	65.1
	60-69	365	20.6	33.7	33.7	38.5	38.6	42.7	42.9	59.6
	>70	116	17.4	28.3	28.5	33.2	33.2	37.2	37.4	58.3
<b>Women</b>	<30	252	22.4	37.4	37.5	42.3	42.4	48.5	48.5	66.7
	30-39	443	20.7	34.3	34.4	39.1	39.1	43.6	43.7	59.0
	40-49	595	20.4	32.5	32.5	37.3	37.3	41.9	42.0	67.1
	50-59	571	13.1	29.4	29.5	33.3	33.4	37.4	37.5	51.0
	60-69	350	17.3	27.0	27.0	30.3	30.4	33.6	33.7	46.6
	>70	105	14.9	22.9	23.0	25.7	25.9	29.2	29.3	66.3

8

9

Supplementary table 2. Hazard ratio for primary end-point by oxygen pulse and ventilatory equivalents

	(n)	HR*	95% CI
Peak oxygen pulse	4,320		
Per unit		0.92	0.87-0.98
Q1		1	
Q2		0.97	0.64-1.47
Q3		0.77	0.49-1.23
Q4		0.32	0.16-0.64
Submaximal EqVO2	2,506		
Per unit		1.05	0.99-1.11
Q1		1	
Q2		0.99	0.48-2.07
Q3		1.06	0.52-2.16
Q4		1.51	0.78-2.92
Peak EqVO2	4,497		
Per unit		1.03	1.00-1.06
Q1		1	
Q2		1.23	0.76-1.98
Q3		1.12	0.69-1.81
Q4		1.50	0.95-2.38
Submaximal EqVCO2	2,503		
Per unit		1.04	0.97-1.13
Q1		1	
Q2		1.27	0.60-2.70
Q3		1.24	0.59-2.62
Q4		1.58	0.77-3.24

Peak EqVCO <sub>2</sub>	4,495		
Per unit	1.04	1.00-1.08	
Q1	1		
Q2	1.18	0.70-1.99	
Q3	1.35	0.81-2.24	
Q4	1.43	0.87-2.35	

---

HR, hazard ratio; CI, confidence interval; Q1 to Q4, quartiles of the respective parameters.

\*Adjusted for age, sex, smoking status, alcohol use, family history of CVD and BMI.

1

2